Form 4: Beta Bionics Director Granted Equity Award

Beta Bionics Director Gerard J. Michel received an award of 3,997 restricted stock units under the company's 2025 Equity Incentive Plan.

Summary

• Gerard J. Michel, a Director of Beta Bionics, Inc. (BBNX), acquired 3,997 shares of common stock.
• The transaction occurred on January 13, 2026.
• The acquisition was an award of restricted stock units (RSUs) granted under the Issuer's 2025 Equity Incentive Plan.
• The acquisition price was $0 per share, which is typical for RSU grants.
• Following this transaction, Mr. Michel directly beneficially owns 16,544 shares of common stock.

Sentiment

Score: 6

Explanation: Slightly positive. Routine equity grant aligns director interests with shareholders, a standard corporate governance practice. No negative surprises.

Positives

• The grant of restricted stock units to a director aligns management and director interests with those of shareholders, incentivizing long-term performance.
• The award is part of the company's established 2025 Equity Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The issuance of new shares (or potential future issuance upon vesting) for equity awards can lead to minor dilution for existing shareholders.

Risks

• Potential future dilution of existing shareholders if a significant number of equity awards are granted and vest.
• The effectiveness of equity incentive plans in motivating performance is subject to market conditions and individual performance.

Future Outlook

The grant of restricted stock units implies a future vesting schedule, designed to incentivize the director's long-term commitment and performance aligned with the company's future success under the 2025 Equity Incentive Plan.

Industry Context

Granting equity awards like restricted stock units is a standard practice in publicly traded companies to compensate directors and executives, align their interests with shareholders, and encourage retention and long-term value creation. This is typical for the biotechnology or medical device industry where long-term development cycles are common.

Comparison to Industry Standards

• Equity compensation for directors, particularly through restricted stock units, is a common practice across industries, including biotechnology and medical devices, to align interests and retain talent.
• The specific number of units granted would typically be benchmarked against peer companies of similar size and stage, such as Insulet Corporation (PODD) or Tandem Diabetes Care (TNDM), though specific comparative data is not provided in this filing.
• The use of an established "2025 Equity Incentive Plan" is standard for public companies to manage and authorize such awards.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential for future dilution from the vesting of RSUs, but generally positive for aligning director incentives with shareholder interests.
• Employees: The 2025 Equity Incentive Plan likely benefits other employees as well, fostering a culture of shared ownership and performance.

Next Steps

• The restricted stock units will vest according to a predetermined schedule, which is not detailed in this Form 4 but is typical for such awards.
• The company will continue to operate under its 2025 Equity Incentive Plan for future equity awards.

Key Dates

Keywords

Beta Bionics, BBNX, Gerard J. Michel, Form 4, insider transaction, restricted stock units, RSU, equity incentive plan, director compensation, stock award